Company intelligence / Profile preview
Unigene Laboratories, Inc.
- Ownership
- Private
- Development stage
- Other
Overview
The company developed Fortical, a nasal calcitonin product for postmenopausal osteoporosis, which received FDA approval in 2005 and was marketed by Upsher-Smith Laboratories. The company also had an oral calcitonin product that completed Phase III testing for osteoporosis treatment and a pre-clinical anorexigenic peptide (UGP281) for obesity.
- Therapeutic areas
- Endocrinology
- Modalities
- Peptides
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Unigene Laboratories, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unigene Laboratories, Inc..